Clinical trial
Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer…
NCT00307229 · Ontario Clinical Oncology Group (OCOG), Other · Completed
Key facts
| NCT number | NCT00307229 |
|---|---|
| Title | Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1) |
| Official title | A Phase I Trial Investigating the Safety and Immunogenicity of an Adenovirus Encoding Rat HER-2 Administered Intradermally to Patients With Metastatic or Locally Recurrent Breast Cancer |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | Ontario Cancer Research Network Canadian Breast Cancer Research Alliance |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer, Recurrent Breast Cancer |
| Intervention type | Biological |
| Interventions | adenoviral vector encoding rat Her-2/neu |
| Enrollment | 8 |
| Start date | Mar 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | May 1, 2012 |
| First posted | Mar 27, 2006 |
| Last update posted | Jun 4, 2012 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: